【レポートの概要（一部）】
1 Chapter 1: Introduction
1.1 Executive Summary
1.2 Topics Covered
1.3 Historical Revenue & Forecast Segmentation
1.4 Key Questions Answered
1.5 Key Findings
1.6 Methodology
1.7 Target Audience
1.8 Companies & Organizations Mentioned
2 Chapter 2: An Overview of Generic Drugs
2.1 What is a Generic Drug?
2.2 Reserve Engineering: How Are Generics Conceived?
2.3 The Concept of Bioequivalence: Are Generics the Same as Innovator Drugs?
2.3.1 What Defines Bioequivalence?
2.3.2 Acceptable Bioequivalence Ranges
2.4 The Question of Brand Quality: Are Generics as Efficient as their Innovator Counterparts?
2.5 Economics: Price Comparison
2.6 Brand Classification: Pure vs. Branded Generics
2.6.1 Pure (Non-branded) Generics
2.6.2 Branded Generics
2.6.3 Super Generics
2.7 Market Growth Drivers
2.7.1 Cost Effectiveness and Affordability
2.7.2 Low Insurance Premiums
2.7.3 Patent Expiry of Innovator Drugs
2.7.4 Political & Regulatory Support
2.7.5 Global Proliferation & Increasing Demand
2.8 Market Barriers
2.8.1 Patent Linkage: Delaying Product Launch
2.8.2 Complex Product Portfolios
2.8.3 Quality Control Issues
2.8.4 Intense Competitive Landscape
2.8.5 Resistance from Big Pharma Players
3 Chapter 3: Regulatory Landscape
3.1 Regional Outlook
3.1.1 Asia Pacific
3.1.2 Europe
3.1.3 Middle East & Africa
3.1.4 Latin & Central America
3.1.5 North America
3.2 International Initiatives
3.2.1 WHO Guidelines
3.2.2 IGDRP (International Generic Drug Regulators Pilot)
3.2.3 EMA (European Medicines Agency): Extending Collaboration beyond the EU
4 Chapter 4: Drug Class Availability & Leading Therapies
4.1 Drug Class Availability
4.1.1 Antibiotics
4.1.2 Cardiovascular & Hypertension
4.1.3 CNS (Central Nervous System)
4.1.4 Dermatology
4.1.5 Diabetes
4.1.6 Gastrointestinal
4.1.7 Hormonal Drugs
4.1.8 Onocology
4.1.9 Pain Relief
4.1.10 Respiratory
4.1.11 Rheumatology
4.1.12 Other Categories
4.2 Leading Generic Drugs
4.2.1 Acetaminophen (Paracetamol)
4.2.2 Alprazolam
4.2.3 Amlodipine
4.2.4 Amoxicillin
4.2.5 Asprin (Acetylsalicylic Acid)
4.2.6 Atenolol
4.2.7 Atorvastatin
4.2.8 Azithromycin
4.2.9 Bendroflumethiazide
4.2.10 Betamethasone Dipropionate
4.2.11 Candesartan
4.2.12 Clavulanic Acid
4.2.13 Clopidogrel
4.2.14 Dexamfetamine
4.2.15 Diclofenac
4.2.16 Doxycycline
4.2.17 Enalapril
4.2.18 Enoxaparin Sodium
4.2.19 Esomeprazole
4.2.20 Fentanyl
4.2.21 Fenofibrate
4.2.22 HCTZ (Hydrochlorothiazide)
4.2.23 Ibuprofen
4.2.24 Lansoprazole
4.2.25 Levothyroxine Sodium
4.2.26 Lisinopril
4.2.27 Losartan
4.2.28 Metformin
4.2.29 Methylphenidate
4.2.30 Methotrexate
4.2.31 Metoprolol
4.2.32 Omeprazole
4.2.33 Pantoprazole
4.2.34 Perindopril
4.2.35 Ramipril
4.2.36 Rosuvastatin
4.2.37 Salbutamol (Albuterol)
4.2.38 Simvastatin
4.2.39 Valsartan
4.2.40 Venlafaxine
4.2.41 Others
5 Chapter 5: Generic Drugs Industry Roadmap & Value Chain
5.1 Industry Roadmap
5.1.1 2015 – 2020: Overtaking Innovator Drugs
5.1.2 2020 – 2025: The Era of Generic Biologics
5.1.3 2025 – 2030 & Beyond: Evolving Regulatory Landscape
5.2 Value Chain
5.2.1 API Manufacturers & Enabling Technology Providers
5.2.1 Generic Drug Manufacturers
5.2.2 Innovator Pharmaceutical Companies
5.2.3 Regional Distributors
5.2.4 Healthcare Providers, Pharmacies & Drug Stores
6 Chapter 6: Key Market Players
6.1 Abbott Laboratories
6.2 AbbVie
6.3 ACETO Corporation
6.4 Acino Holding
6.5 Actavis
6.6 Actelion
6.7 Adcock Ingram
6.8 Ajinomoto
6.9 Akron
6.10 Alexion Pharmaceuticals
6.11 Alfa Wasserman
6.12 Amgen
6.13 AMRI (Albany Molecular Research, Inc.)
6.14 Amneal Pharmaceuticals
6.15 Apotex
6.16 ASKA Pharmaceutical Company
6.17 Aspen Holdings
6.18 Astellas Pharma
6.19 AstraZeneca
6.20 Aurobindo Pharma
6.21 Baxter BioScience
6.22 Bayer AG
6.23 BD (Becton, Dickinson and Company)
6.24 Biogen Idec
6.25 Biocon
6.26 Boehringer Ingelheim
6.27 BMS (Bristol-Myers Squibb)
6.28 Cadila Healthcare (Zydus Cadila)
6.29 Cadila Pharmaceuticals
6.30 Celgene Corporation
6.31 Chiesi Farmaceutici
6.32 Chugai Pharmaceutical Company
6.33 Claris Lifesciences
6.34 Cipla
6.35 Coherus BioSciences
6.36 Consort Medical
6.37 Daiichi Sankyo
6.38 Dong-A Pharmaceutical
6.39 Dr. Reddy’s Laboratories
6.40 Eisai Company
6.41 Eli Lilly and Company
6.42 Endo International
6.43 ESTEVE Group
6.44 Eurofarma Laboratorios
6.45 Ferring Pharmaceuticals
6.46 Fresenius Kabi
6.47 Fujifilm Pharma Company
6.48 Fuji Pharma Company
6.49 Galderma
6.50 Galenika
6.51 Gedeon Richter
6.52 Genepharm
6.53 Gilead Sciences
6.54 Glenmark Pharmaceuticals
6.55 Grifols
6.56 Gruenenthal Group
6.57 GSK (GlaxoSmithKline)
6.58 Hanmi Pharmaceutical Company
6.59 Hetero Drugs
6.60 Hikma Pharmaceuticals
6.61 Hospira
6.62 Impax Laboratories
6.63 Ipsen
6.64 JT (Japan Tobacco)
6.65 Jazz Pharmaceuticals
6.66 Johnson & Johnson
6.67 Kaken Pharmaceutical Company
6.68 Kaneka Corporation
6.69 Kowa Company
6.70 Kremers Urban Pharmaceuticals
6.71 Krka (Krka, d. d.)
6.72 Kyowa Hakko Kirin Company
6.73 Laboratorios Roemmers
6.74 Leo Pharma
6.75 Les Laboratoires Servier
6.76 Lundbeck (H. Lundbeck A/S)
6.77 Lupin
6.78 Mallinckrodt
6.79 Maruho Company
6.80 Meda
6.81 Meiji Holdings
6.82 Menarini Group
6.83 Merck and Co.
6.84 Merck KGaA
6.85 Merz Pharma
6.86 Mitsubishi Tanabe Pharma
6.87 Mitsui & Company
6.88 Mylan
6.89 Natco Pharma
6.90 Nichi-Iko Pharmaceutical Company
6.91 Nippon Kayaku
6.92 Nippon Shinyaku
6.93 Nipro Pharma Corporation
6.94 Novo Nordisk
6.95 Ono Pharmaceutical Company
6.96 Orion Corporation
6.97 Otsuka Holdings Company
6.98 Par Pharmaceutical Companies
6.99 Perrigo Company
6.100 Pfizer
6.101 Pharmstandard
6.102 Pierre Fabre (Laboratoires Pierre Fabre)
6.103 Piramal Enterprises
6.104 Pliva (Pliva d.d.)
6.105 Prasco Laboratories
6.106 Purdue Pharma
6.107 Ranbaxy Laboratories
6.108 Recordati
6.109 Regeneron Pharmaceuticals
6.110 Roche Holding (F. Hoffmann-La Roche)
6.111 Salix Pharmaceuticals
6.112 Samsung Group
6.113 Sandoz International (Novartis International)
6.114 Sanofi
6.115 Santen Pharmaceutical Company
6.116 Sawai Pharmaceutical Company
6.117 Seikagaku Corporation
6.118 Sequent Scientific
6.119 Shionogi & Company
6.120 Shire
6.121 Sigma-Tau
6.122 STADA Arzneimittel
6.123 Strides Arcolab
6.124 Sumitomo Dainippon Pharma Company
6.125 Sun Pharmaceutical Industries
6.126 Taisho Pharmaceutical Holdings Company
6.127 Takeda Pharmaceutical Company
6.128 Teijin
6.129 Teva Pharmaceutical Industries
6.130 The Medicines Company
6.131 Torrent Pharmaceuticals
6.132 Towa Pharmaceutical Company
6.133 UCB
6.134 United Therapeutics Corporation
6.135 Valeant Pharmaceuticals International
6.136 Vertex Pharmaceuticals
6.137 Wockhardt
7 Chapter 7: Market Analysis & Forecasts
7.1 Global Outlook of Generic Drugs
7.2 Segmentation by Brand Classification
7.2.1 Pure (Non-branded) Generics
7.2.2 Branded Generics
7.2.3 Super Generics
7.3 Segmentation by Therapeutic Area
7.3.1 Antibiotics
7.3.2 Cardiovascular & Hypertension
7.3.3 CNS
7.3.4 Dermatology
7.3.5 Diabetes
7.3.6 Gastrointestinal
7.3.7 Hormonal Drugs
7.3.8 Oncology
7.3.9 Pain Relief
7.3.10 Respiratory
7.3.11 Rheumatology
7.3.12 Others
7.4 Segmentation by Region
7.4.1 Asia Pacific
7.4.2 Europe
7.4.3 Middle East & Africa
7.4.4 Latin & Central America
7.4.5 North America
7.5 Top Country Markets
7.5.1 Brazil
7.5.2 Canada
7.5.3 China
7.5.4 Egypt
7.5.5 France
7.5.6 Germany
7.5.7 Greece
7.5.8 India
7.5.9 Israel
7.5.10 Italy
7.5.11 Japan
7.5.12 Mexico
7.5.13 Netherlands
7.5.14 Poland
7.5.15 Portugal
7.5.16 Russia
7.5.17 Saudi Arabia
7.5.18 South Africa
7.5.19 South Korea
7.5.20 Spain
7.5.21 Switzerland
7.5.22 Taiwan
7.5.23 Turkey
7.5.24 UK
7.5.25 USA
8 Chapter 8: Conclusion & Strategic Recommendations
8.1 Why is the Market Poised to Grow?
8.2 Are Generic Drugs Becoming Expensive?
8.3 Competitive Industry Landscape: Acquisitions, Alliances & Consolidation
8.4 High Profile Recalls: What is the Impact on the Market?
8.5 Lower-Cost Countries: Increasing R&D and Manufacturing Investments
8.6 Geographic Outlook: Which Countries Offer the Highest Growth Potential?
8.7 Prospects of Biosimilars
8.7.1 How Big is the Biosimilars Opportunity?
8.7.2 Regulatory Status
8.8 Strategic Recommendations
8.8.1 Generic Drug Manufacturers
8.8.2 Innovators
【レポート販売概要】
■ タイトル：後発医薬品の世界市場：機会、課題、戦略、市場予測■ 英文：The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts
■ 発行日：2015年2月
■ 調査会社：Signals and Systems Telecom
■ 商品コード：DATA5022408
■ 調査対象地域：グローバル
- ソーシャル及び検知システムにおけるビックデータ収集：市場機会と課題2013-2019（Capturing Big Data in Social and Detection Systems: Market Opportunities and Challenges 2013 -2019）Every large corporation collects and maintains a huge amount of data associated with its customers including their preferences, purchases, habits, travels, and other personal information. In addition to the large volume, much of this data is unstructured, making it hard to manage. This so called “Big Data” is a challenge for industry verticals yet also an opportunity. The enormous growth potential …
- 企業向けLMS（学習管理システム）の世界市場2017-2021About Corporate LMS LMS are software applications that are used to plan, deliver, and manage learning process. They use web-based technology to manage, administer, track, and report on the delivery of content, and evaluate the performance of participants. A large number of corporates are widely adopting these solutions due to the substantial cost benefits and proven results of increased efficiency …
- 食物アレルギー(Food Allergy)：治療薬開発パイプライン動向（2015年上半期版）Food Allergy - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Food Allergy - Pipeline Review, H1 2015’, provides an overview of the Food Allergy’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Food Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), ro …
- ガス・ツー・リキッド（GTL）の世界市場2019-2023About this market Owing to an increase in the supply of coalbed methane, tight gas, and shale gas, natural gas has turned out to be the fastest-growing fossil fuel. Hence, the global oil and gas industry has been experiencing rapid growth in terms of the production of unconventional oil and gas resources. Therefore, the growth in natural gas production ensures the availability of natural gas to fu …
- 医薬品リーダーシリーズ：医薬品製造受託機関（CMO）上位30社2016-2026In its updated report, visiongain provides revenues to 2026 for the world pharmaceutical contract manufacturing organisations (CMO) market. This report also analyses leading companies in pharmaceutical contract manufacturing. The demand for outsourced drug production has grown rapidly in the past 10 years. The world market for pharma contract manufacturing was worth $61.6bn in 2015, having grown b …
- ゲノム編集の世界市場分析：技術別（CRISPR、TALEN、ZFN）、送達方法別（体外、体内）、用途別（動物/植物細胞の編集）、サービス別（インハウス、委託）、エンドユーザー別、セグメント予測、2014-2025The global genome editing market is anticipated to reach USD 8.1 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers attributing to the expansion include early applications of DNA editing to therapeutics. Use of the technology for the disease eradication through direct correction of disturbances in normal physiology, engineering the immune response, and alteration o …
- 世界のホームオートメーション及び制御市場：照明制御、セキュリティ制御、HVAC制御などOff late, the home automation and controls have not only led to power savings but have also enhanced the living standards, in turn, offering a convenient life. This report, based on the extensive research study on home automation & controls market, is aimed at identifying the entire market of home automation & controls; specifically, lighting control, security control, access control, HVAC control …
- 世界のタバコ市場（2015年2月版）Summary “Tobacco Insights 2015 - February” is a new report that is the result of ERC's extensive market research covering the global tobacco market. It provides an analysis of changing production and consumption patterns and the recent developments impacting the tobacco market. It provides a regional analysis of cigarette consumption including import and export share by region. Key Findings - Acco …
- 麻ベース食品の世界市場2016-2020About Hemp Hemp is a sustainable crop, which is seeded toward the end of May or during early June. The hemp plants are grown close together and possess large and broad leaves. The harvesting of hemp begins around 120 days after seeding. Scientists believe that humans have been cultivating hemp for over ten thousand years, owing to its nutritional, medicinal, and industrial properties. As a crop, h …
- LBS、技術、エコシステムに関する理解：Understanding Location-based Services (LBS), Technology, and the LBS EcosystemThis provides the reader with a complete understanding of location-based services (LBS) technology, applications, and the LBS ecosystem. It is a must read for anyone who wants to identify opportunities within LBS and better understand how to integrate their products/services with location. This is provided in PowerPoint (PPT) format with multimedia environment including instructor “voice-over” dis …
- パニック障害治療のグローバル臨床試験動向（2014年下半期）Panic Disorders Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Panic Disorders Global Clinical Trials Review, H2, 2014" provides data on the Panic Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Panic Disorders. It includes an overview of the trial numbers and their recruitment status as …
- 非在来型ガスの世界市場予測・分析2020-2024Global Unconventional Gas Market: About this market Technavio’s unconventional gas market analysis considers sales from shale gas, tight gas, and coalbed methane types. Our study also finds the sales of unconventional gas in APAC, EMEA, and the Americas. In 2019, the shale gas segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as r …
- 世界の高級ホテル市場Summary The global luxury hotels market's performance has recovered from the slowdown recorded at the beginning of the historic period (2009-2013) due to the financial crisis and recession. Overall, growth was recorded in the four markets - Americas, Asia-Pacific, Europe, Middle East and Africa - across all key performance indicators (KPIs) during the historic period. Growth is expected to continu …
- 放射線治療の世界市場予測（～2023年）“The radiotherapy market is projected to grow at a CAGR of 4.1% during the forecast period”The global radiotherapy market is projected to reach USD 6.8 billion by 2023 from USD 5.6 billion in 2018, at a CAGR of 4.1%. Growth in this market is largely driven by factors such as the growing global prevalence of cancer, increasing adoption of radiotherapy in clinical trials, and the increasing number o …
- 世界のUV（紫外線）殺菌装置市場About UV Light Disinfection UV irradiation offers the effective and rapid inactivation of microorganisms. Bacteria, viruses, and protozoa are rendered incapable of reproduction and infection after exposure to the germicidal wavelength of UV light. It prevents the reproduction by damaging the nucleic acids of the organism. UV light has exhibited efficacy against pathogenic organisms and chemical co …
